ArticleScientific reports2025
ABCE1 facilitates tumour progression via aerobic glycolysis and inhibits cell death in human colorectal cancer cells through the p53 signalling pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Profound alterations of cancer transcriptomes by the RNase L inhibitor ABCE1 through the modulation of UU/UA-dinucleotide rich transcript abundance.RNA biology · 2026Article
- Tyrosinase Structural Perturbation and Functional Inhibition by an Ostrich-Derived Keratin-Diospyros lotus Nanobiocomposite: Biochemical Mechanism and Melanoma Cell Response.The protein journal · 2026Article
- Development of a prognostic prediction model incorporatingJournal of gastrointestinal oncology · 2026Article
- Kabbe condensation: a comprehensive review of spirochromanone synthesis and medicinal applications.RSC advances · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) poses a formidable challenge to global health, necessitating the quest for novel biomarkers to improve therapeutic strategies. This study explores ABCE1 (ATP-binding cassette subfamily E member 1) as a potential biomarker for CRC and delves into its intricate molecular mechanisms. Through integrated bioinformatic analyses, this study underscores the significant oncogenic role of ABCE1 in CRC, opening new avenues for promising therapeutic interventions. Deletion of ABCE1 reduced cell growth, abrogated aerobic glycolysis, and promoted apoptosis in HT-29 and HCT-116 cells. Further validation through experimentation with irinotecan revealed compelling outcomes, including diminished cell growth, induces G1 phase cell cycle arrest, and promotes apoptosis in HCT-116 and HT-29 colorectal cancer cells. ABCE1 KO with irinotecan combined treatment significantly increased the inhibition of cell proliferation and aerobic glycolysis in CRC cells, accentuating the multifaceted role of ABCE1 in CRC progression. Moreover, this work also demonstrated the complex relationship between ABCE1 and the p53 signalling pathway, which was confirmed in experimental assays. These assays also revealed that deletion of ABCE1 with irinotecan might regulate G1 phase cell cycle arrest, inhibit metabolic regulation, and activate the p53 pathway to induce apoptosis in HCT-116 cells. Molecular docking analyses further supported these findings, revealing the strong binding affinity of irinotecan for targets of the p53 signalling cascade. Collectively, these comprehensive insights support the potential therapeutic efficacy of targeting ABCE1 in CRC treatment strategies. Overall, the findings from this study underscore the importance of ABCE1 as a potential biomarker in CRC and illuminate its complex molecular mechanisms. The demonstrated effectiveness of ABCE1 inhibition, particularly through irinotecan, coupled with its interplay with crucial signalling pathways such as p53, highlights its potential as a promising therapeutic option for colorectal cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.